Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.
10.1172/jci.insight.137230 Vieira et al. JCI Insight
Vieira CP, Fortmann SD, Hossain M, Longhini AL, Hammer SS, Asare-Bediako B, Crossman DK, Sielski MS, Adu-Agyeiwaah Y, Dupont M, Floyd JL, Li Calzi S, Lydic T, Welner RS, Blanchard GJ, Busik JV, Grant MB
Study details